TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lipocine ( (LPCN) ) has shared an update.
On November 18, 2025, Lipocine announced promising interim safety results from its Phase 3 clinical trial of LPCN 1154, an oral brexanolone formulation for postpartum depression (PPD). The Drug Safety Monitoring Board recommended the trial continue as planned, with no serious adverse events reported among participants. The trial’s success could position LPCN 1154 as a game-changing treatment for PPD, with topline results expected in the second quarter of 2026, potentially supporting a New Drug Application submission.
The most recent analyst rating on (LPCN) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Lipocine stock, see the LPCN Stock Forecast page.
Spark’s Take on LPCN Stock
According to Spark, TipRanks’ AI Analyst, LPCN is a Neutral.
Lipocine’s overall stock score is primarily impacted by its financial performance and valuation. While the company shows signs of financial recovery with a strong balance sheet, ongoing profitability challenges and negative cash flow generation weigh heavily on the score. The technical analysis indicates a bearish trend, further contributing to the lower score. The lack of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on LPCN stock, click here.
More about Lipocine
Lipocine Inc. is a biopharmaceutical company that utilizes its proprietary technology platform to develop innovative products with effective oral delivery. The company’s development pipeline includes drug candidates targeting large addressable markets with significant unmet medical needs, such as postpartum depression, treatment-resistant depression, epilepsy, essential tremor, obesity management, liver cirrhosis, and preterm birth prevention. Lipocine also has an FDA-approved product, TLANDO, for conditions associated with testosterone deficiency in adult males.
Average Trading Volume: 33,793
Technical Sentiment Signal: Sell
Current Market Cap: $15.93M
Learn more about LPCN stock on TipRanks’ Stock Analysis page.